CBS 2019
CBSMD教育中心
中 文

急性冠脉综合征

Abstract

Recommended Article

An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial Dynamic Myocardial Ultrasound Localization Angiography Utility and Challenges of an Early Invasive Strategy in Patients Resuscitated From Out-of-Hospital Cardiac Arrest Homeostatic Chemokines and Prognosis in Patients With Acute Coronary Syndromes Prevalence of Angina Among Primary Care Patients With Coronary Artery Disease Systems of Care for ST-Segment–Elevation Myocardial Infarction: A Policy Statement From the American Heart Association Multivessel Versus Culprit-Vessel Percutaneous Coronary Intervention in Cardiogenic Shock Complete Revascularization Versus Culprit Lesion Only in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A DANAMI-3-PRIMULTI Cardiac Magnetic Resonance Substudy

Original ResearchMay 11,2024

JOURNAL:Lancet Article Link

Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial

葛震、阚静、高晓飞、陈绍良、Gregg W. Stone

Full Text PDF